, and endoscopic OCT is being commercialized as an adjunct to conventional white-light endoscopic examination 2 . OCT has also been applied to preclinical imaging. In the past few years, exciting achievements in intravital cancer imagingthat is, imaging of tumours in living mouse models -have underscored a growing role for OCT in preclinical imaging. In this Innovation article, we highlight how recent advances in OCT have provided new imaging capabilities in cancer biology, and how these capabilities contrast with those provided by existing technologies. We highlight successful preclinical applications of OCT from multiple laboratories for imaging different aspects of the biology of tumours and their microenvironments, and how OCT can be integrated with complementary imaging modalities to enhance the information that is obtained from imaging studies. Finally, we discuss the potential of using OCT to monitor the clinical treatment of cancer.
OCT instrumentation
OCT is one of many techniques for imaging tissues and cells in a living organism (TABLE 1 ). An OCT system typically comprises a light source, an interferometer and a microscope or imaging catheter that delivers light to, and collects reflections from, the tissue to be imaged
. Because of optical scattering in tissue, OCT signals cannot penetrate beyond 2 mm in most tissues. This necessitates the selection of appropriate animal models. Often, as with fluorescence microscopies that have limited imaging depths, benchtop (non-endoscopic) imaging is carried out using window models at the skin, mammary fat pad or brain sites [7] [8] [9] . OCT can also be used for subcutaneous models by transdermal imaging and can be applied to surgically exposed internal sites 10 . Benchtop imaging uses a microscope that is similar in its design to those that are used in fluorescence microscopy in which anesthetized animals are placed under the imaging objective and galvanometric beam scanners translate the imaging beam. As an alternative to benchtop OCT, endoscopic OCT allows imaging at internal sites within the animal 11, 12 : the probe is placed in contact with or very near to the tissue to be imaged. This miniaturization does not typically induce substantial degradation in imaging sensitivity or resolution. Beyond providing access to internal sites in small animals, these endoscopic embodiments are also the most likely pathway for the potential future clinical adoption of OCT tools with which to monitor cancer therapy.
Image contrast applications of OCT Fundamentally, OCT measures how light propagates in tissue and how it scatters from tissue structures. Over the past decade, our ability to translate these measurements into physiological and anatomical parameters has expanded considerably. The methods used to relate OCT signals to anatomical measures that are relevant to cancer are summarized below and are contrasted with similar measurements that use alternative intravital approaches.
Microstructural imaging. Structural (anatomical) imaging is used to measure tumour volume, to locate tumours anatomically or to define the tumour microenvironment. Intravital ultrasound 13 and micro-computed tomography (μCT) 14 are commonly used for this purpose. Both have the advantage of large imaging fields and deep penetration, but they are both also hindered by fairly poor soft-tissue contrast, which limits the interpretation of the anatomy.
Microstructural images can be generated from OCT measurements by using the logscale magnitude of optical scattering. Because optical scattering is more varied across soft tissues than either acoustic scattering or X-ray absorption, microstructural OCT images generally provide greater contrast than ultrasound or contrast-free computed tomography. This increases the ability to detect tumour margins, and more broadly elucidates the microenvironment at the tumour site. Because OCT penetration is limited to 2 mm, measuring the volume of larger tumours is more suited to ultrasound and computed tomography methodologies. Microstructural OCT imaging can be carried out rapidly: an 8 mm by 8 mm by 2 mm field at 10 μm resolution takes less than 5 seconds to acquire using current instrumentation 14 .
Viability imaging. Imaging viability within a tumour model helps to elucidate the spatially heterogeneous response to therapy.
However, methods for intravital imaging of viability are limited. Micro-positron emission tomography (μPET) scanners using 18 F-fluorodeoxyglucose ( 18 F-FDG) labelling can map viability in whole-body imaging studies, but their limited resolution (typically greater than 1 mm) is not well matched to the size of tumours in small animal models 15 . Fluorescent deoxyglucose analogues 16 have been shown to allow optical monitoring of glucose uptake activity in culture 17 and in vivo 18, 19 , and may provide alternatives to PET-based methods. Green fluorescent protein (GFP)-expressing tumours can be used to monitor viability, as the fluorescent protein carrier has an approximately 36-hour half-life [20] [21] [22] , but these techniques are restricted by imaging field and depth. Luciferase reporter bioluminescence (for example, firefly, gaussia and renilla luciferase) can also be used to image cell viability at lower spatial resolutions 23 .
OCT can discriminate between viable and non-viable compartments of the tumour through correlated changes in optical scattering 10 . Although the underlying changes in tissue structure that modulate optical scattering have not been identified, a correlation between high scattering and loss of viability has been confirmed by registered images and histology. However, caution must be used when associating scattering changes to viability status, as other processes could manifest similar scattering changes. OCTbased viability imaging has the advantage of being label-free, and can be easily carried out concurrently with other OCT imaging modalities -for example, microstructural imaging; both contrast methods operate on the same acquired data set and are differentiated only by post-processing. The paucity of robust methods for imaging tumour viability in preclinical settings makes this a compelling application for OCT.
Lymphangiography. Lymphatic vessels have a central role in solid tumour growth and metastasis 24 . The disruption of normal lymphatic function by solid tumours contributes to the high interstitial fluid pressure within the solid tumour and hinders convective drug transport 25 . Conversely, peri-tumour lymphatic vessels provide a route for metastasis. There is, therefore, a need to image lymphatic vessels in solid tumour microenvironments and in response to cancer therapies. However, lymphatic imaging remains one of the most considerable challenges in intravital microscopy because, unlike the blood vasculature, the lymphatic system cannot be easily systemically labelled. The most common technique that is currently available requires tracer injection into the site (for example, into the tumour or the surrounding host tissue) 26 . As lymphatic vessels collect and are filled with the injected tracers, they can be imaged by either wide-field cameras or fluorescent microscopy. This approach, however, only reveals a partial network and it perturbs lymphatic vessel physiology.
OCT can be used for label-free lymphangiography 10, 27 . Contrast for the lymphatics is derived from the difference in optical scattering between lymph fluid, which is nearly transparent, and tissue, which is highly scattering. The lymphatic network appears in three-dimensional data sets as hypoechoic (low-scattering) regions; three-dimensional connectivity, as well as characteristic valve and lymphangion morphology, make the identification of lymphatics fairly straightforward. Because a proportion of the lymphatic vasculature is collapsed at any given time in normal physiology, comprehensive mapping is not always possible. Higher resolution embodiments of OCT that are able to detect lymphatic vessels with smaller open luminal areas are technically feasible and would mitigate this limitation.
Box 1 | Principles of OCT
In its simplest form, an optical interferometer is an instrument that is capable of measuring the differential distance travelled by two paths of light (see the figure, part a). It operates by splitting a light source into two beams, with each beam made to travel one of the two paths that are to be compared. When these beams are recombined, their resulting interference signal depends on the distance (at the sub-micron scale) travelled by each beam. In optical coherence tomography (OCT), this concept is extended using one of the two beams of the interferometer to illuminate living tissue (see the figure, part b) . As the beam propagates into the tissue, scattering by cells and other structures redirects some light backwards. This scattered light is collected and made to interfere with the second (mirror-reflected) beam. Using the resulting interference signal, the depth of all the tissue-scattered light can be measured to the limit of the resolution of the interferometer, which is typically 5-10 μm in OCT systems. Transverse resolution is limited by the focused beam size and varies from 5 μm to 30 μm depending on the system design. Repeating these measurements across three dimensions allows an OCT instrument to map optical scattering across the tissue volume with near-histological resolution. By analysing these optical scattering measurements, properties including anatomy, blood vasculature (see the figure, part b) , lymphatic vasculature and tissue viability can be measured.
Angiography. Understanding tumour angiogenesis and the response of tumours to vascular-targeting therapies have been major themes in cancer research over the past decade [28] [29] [30] . Current approaches for intravital angiography include Doppler ultrasound, micro-magnetic resonance imaging (μMRI), μCT, photoacoustic tomography [31] [32] [33] [34] and fluorescent microscopy. Of these, ultrasound, and μMRI-and μCT-based methods, cannot resolve single vessels owing to limited resolution. To date, fluorescence angiography has been most broadly adopted to study angiogenesis in tumour models at the resolution of individual vessels 35 . Fluorescent methods, however, require systemic labelling of the vasculature through intravenous injection, which carries known limitations in longitudinal studies 8 . Using microstructural OCT, some large vessels that exceed 100 μm in diameter can be visualized. To extend contrast to smaller vessels, alternative methods based on blood flow are commonly used in OCT. Unlike microstructural, viability and lymphatic methods of contrast, angiographic imaging relies on the measurement of scattering dynamics. Flowing blood modulates optical scattering, and this modulation can be detected and used to differentiate between the intravascular and extravascular compartments of the tumour. Unlike fluorescent approaches, OCT-based angiography is label-free. OCT and fluorescence angiography are further differentiated by their fields, imaging depths and resolutions (TABLE 1) , with fluorescence microscopy providing smaller fields and a higher resolution than OCT.
Unlike architectural, viability and lymphatic OCT imaging, angiographic OCT monitors scattering changes over time and so requires strict animal immobilization. In a typical setup, the site to be imaged must be mechanically immobilized through the use of window chamber models or other mechanical restraints. When immobilizing the site, however, care must be taken to prevent occlusion of the vasculature and loss of vascular contrast in response to mechanical pressure. Angiographic OCT methods also require longer imaging times to capture the scattering dynamics at each location. Depending on the algorithm used, and the blood flow sensitivity required, imaging of an 8 mm by 8 mm by 2 mm field at 10 μm resolution takes 1-20 minutes, compared with ~5 seconds for non-dynamic contrast modes of OCT 10 . Longer imaging times allow for more extensive sampling of the signal dynamics, which leads to improved image contrast. Refinements in algorithms are likely to reduce this time in the near future.
Additional contrast modes in OCT.
Several additional imaging contrast modes are available in OCT but they are either at earlier stages of development or have not yet been shown to be relevant to cancer studies, and so they are not discussed in detail here. These additional contrast modes include techniques for detecting exogenous labels, which could enable OCT-based measurements of drug distribution within tumours 36 . Also possible is the use of OCT for identifying specific tissue components, such as collagen and muscle fibres, by measuring their influence on the polarization of the incident light field 37 . This polarization-sensitive OCT approach is fairly well established, and may be useful for probing tumour-stroma interactions. Finally, careful measurements of scattering dynamics may yield contrast for cellular processes such as apoptosis 38 or may allow for comprehensive quantification of blood flow velocity in a tumour vascular network.
OCT in preclinical cancer research
Investigators have adopted these OCT methods to study cancer biology and to evaluate drug response in preclinical settings. Recent accomplishments are discussed below, with an emphasis on applications in which OCT provided measurements that would be difficult or impossible to obtain using alternative modalities.
The usefulness of microstructural OCT has been demonstrated in several studies. In one study, OCT was used to measure the volume of tumours implanted in dorsal skinfold chambers 10 . This study used a manual segmentation approach to delineate the tumour margins in three dimensions (FIG. 1a) . From these margins, the tumour volume was calculated and used both to define consistent therapeutic start points across animals in an anti-angiogenic drug study, and to demonstrate growth delay in response to vascular endothelial growth factor receptor 2 (VEGFR2) blockade. By acquiring architectural and vascular OCT images simultaneously, the authors were able to use these tumour margins to further segment intratumoural and peri-tumoral vessels, enabling the differential analysis of vascular response at these sites. The expanded field, imaging depth and multimodal imaging provided by OCT make these analyses possible.
Microstructural OCT was also used endoscopically to image disease progression in induced models of colorectal cancer 11 . These authors were able to (FIG. 1b) . In this work, they also demonstrated that microstructural OCT-based contrast could be used to image nanoshells that were targeted to epidermal growth factor receptor (EGFR). This endoscopic OCT system was also combined with fluorescence imaging to correlate early disease (identified by microstructural OCT), with increased VEGFR2 expression (identified by fluorescence labelling). In these endoscopic applications, the resolution and soft-tissue contrast afforded by OCT allowed the earlier detection of lesions than would have been possible using μCT and μMRI.
The ability of OCT to monitor celltargeted therapy was demonstrated by viability imaging in xenograft models that were given a diphtheria toxin, which served as a proxy for a tumour cell-targeted therapy. The toxicity of diphtheria toxin is highly species-specific, hence it is acutely toxic to human tumour cells but it is not toxic to mice 10 . Changes in scattering within the tumour volume were quantified across time to track changes in tumour viability (FIG. 1c) . Again, simultaneous architectural and vascular imaging provided correlated measures of tumour volume and vascular response.
OCT-based lymphangiography has been used to map lymphatic vessels in the peri-tumour space both in dorsal skinfold chamber models and in ear models 10 . Quantification of peri-tumour lymphatic hyperplasia was shown to be correlated with the distance to the tumour margin in human sarcoma models, and longitudinal tracking of single peri-tumour lymphatic vessels was demonstrated 10 . Some of the most compelling applications of OCT in preclinical cancer research have been in the area of angiography. The ability of OCT to repeatedly image over broad fields makes it ideal for studies of tumour angiogenesis and vascular response across a variety of sites 10 . In a recent study, a novel therapeutic strategy using a bioengineered von Hippel-Lindau (VHL) protein was used to induce the degradation of hypoxia-inducible factor 1α (HIF1α) and HIF2α. OCT was used to characterize angiogenesis in xenograft models that were treated with VHL 39 . In combination with fluorescence microscopy, which was used to confirm adenovirus delivery of VHL, the study demonstrated robust inhibition of angiogenesis and increased tumour necrosis following treatment. In a further example of hybrid studies that combine OCT with other modalities, an instrument that was capable of dynamically imaging oxygen supply and demand in tumours was also demonstrated 40 . In this model, OCT was used to measure blood flow while spectroscopic techniques provided measures of blood oxygenation (using haemoglobin spectroscopy) and metabolic demand (using 'redox ratio' fluorescence measurements).
The wide-field imaging of OCT reveals the morphological nature of tumour vascular networks with a unique clarity. This capability was used to highlight the important role of the microenvironment in tumour vasculature 10 (FIG. 2) . Frequently repeated angiography -which is not practical using fluorescence microscopy owing to imaging time and accumulation of extravasated label -is possible using OCT. OCT techniques were used for time-lapse angiography and microstructural imaging of tumours in response to VEGFR2 blockade 10 (Supplementary information S1 (movie)). OCT imaging was carried out every 2 hours for a period of 48 hours in order to capture the rapid vascular changes that are induced by VEGFR2 blockade. Microstructural imaging confirmed that, despite these vascular changes, the vascular-targeted therapy did not affect the tumour growth during this time.
OCT in clinical response monitoring Many preclinical imaging approaches, although they are very effective, are not translatable to the clinic because they rely on genetic modifications or because they would require regulatory approval of a new label. OCT has moved rapidly into diagnostic applications generally because it is label-free and thereby circumvents these translational challenges. With the growth in OCT-based imaging of cancer demonstrated in preclinical settings, there is a strong argument for efforts to translate The image shows the contrast at different tissue depths (shown in the vertical direction) versus distance along the colon (shown in the horizontal direction). Disease progression -from normal tissue to gastrointestinal intraepithelial neoplasia (GIN) and to adenoma -can be monitored through hallmark modifications, such as the loss of tissue stratifications. c | By quantifying scattering in OCT microstructural data sets, tumour viability can be monitored during cytotoxic interventions. Here, representative viability images of a LS174T human colorectal adenocarcinoma xenograft in a dorsal skinfold chamber model are presented either 2 days after administration of diphtheria toxin (lower panel) or as an untreated xenograft at the same time point (upper panel) 10 . Increases in scattering that indicate significant loss of viability are evident in the diphtheria toxin-administered animal. 
Conclusions and perspectives
OCT is an established diagnostic method and it is increasingly being adopted in preclinical cancer research. OCT provides imaging capabilities that fill specific gaps in existing intravital approaches, and may, therefore, become a commonly used technology in the biological laboratory. Of course, the anatomical contrast provided by OCT would be complemented by the molecular insight provided by labelled approaches. Therefore, multi-modality imaging should be used in preclinical settings. The growth of both research into and commercial industry backing of OCT will continue to yield advances in performance and broaden access to the instrumentation, further driving adoption of OCT in the clinic.
A need for imaging biomarkers in cancer offers an exciting role for OCT in clinical therapy monitoring. Currently, vascular imaging biomarkers derived from clinical whole-body imaging modalities such as MRI are used to assess therapies [45] [46] [47] [48] [49] . With the development of appropriate probes, it may be possible to use OCT techniques to provide a higher resolution visualization of the vasculature within tumours. Studies that confirm a correlation between OCTderived images and therapeutic response are needed, and accessible tumours that require minimal probe development, such as skin and oral cancers, may present the earliest opportunities for these studies. Abstract | Recent research has raised hopes for impressively accurate screening for cancer with molecular biomarkers. These molecular markers will probably be more sensitive and specific than older screening modalities, as well as easier to use. In this Essay, I argue that these sensitive screening tests might be clinically valuable -but that they will present unique issues in implementation and interpretation. These issues are likely to affect the way clinicians conduct screening and the way that they make diagnoses in individuals who screen positive for cancer.
Newer proteomic and genetic technologies have invigorated research into cancer screening, but the use of molecular biomarkers for the early detection of cancer is not new. Testing stools for haem and measuring levels of serum prostate-specific antigen (PSA) are established screening modalities for bowel and prostate cancer, respectively, with each method relying on the detection of particular molecular entities. Carcinoembryonic antigen (CEA) and cancer antigen 125 (CA-125) are other familiar molecular biomarkers that were found to be ineffective for screening, but that are currently used for follow-up assessments in patients with colorectal and ovarian cancer, respectively [1] [2] [3] . In developed countries, the general public has high expectations for cancer screening that seemingly extend beyond the evidence for its efficacy 4, 5 . Potentially, screening with molecular biomarkers could help to meet these expectations, but recent reports of striking accuracy for some molecular screens 6, 7 have not been confirmed 8, 9 .
Nonetheless, there is considerable on-going research, and new molecular cancer markers for several cancers are likely to reach the clinic 10 . This Essay considers the uses and the interpretation of molecular biomarkers for detecting cancer as part of a screening process -taking advantage of the knowledge gained from more traditional screening tests and the experience to date with familiar molecular markers, such as PSA and stool haem testing.
Molecular and anatomical screening
Many established screening tests are explicitly designed to detect tumour masses, and in this sense they are 'anatomical' . This is clearly the case for almost all radiographic screening (mammography and chest X-rays, for example), physical examination (such as, breast and pelvic examinations) and endoscopy. Because some benign masses can look like cancer, there are false-positive anatomical screens. For example, lung cancer screening with computed tomography detects small nodules that are often benign remnants of infections or of inflammatory
